Morgan Stanley Next Cure, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Next Cure, Inc. stock. As of the latest transaction made, Morgan Stanley holds 402,258 shares of NXTC stock, worth $619,477. This represents 0.0% of its overall portfolio holdings.

Number of Shares

402,258

Previous 80,828 397.67%

Holding current value

$619,477

Previous $92,000 875.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.13 - $2.23 $363,215 - $716,788	321,430 Added 397.67%	402,258 $897,000
Q4 2023 Feb 13, 2024	BUY	$1.03 - $1.45 $83,251 - $117,199	80,827 Added 8082700.0%	80,828 $92,000
Q3 2023 Nov 15, 2023	SELL	$1.29 - $1.84 $387 - $552	-300 Reduced 99.67%	1 $0
Q2 2023 Aug 14, 2023	SELL	$1.47 - $1.86 $173,517 - $219,552	-118,039 Reduced 99.75%	301 $0
Q1 2023 May 15, 2023	BUY	$1.46 - $1.83 $128,452 - $161,005	87,981 Added 289.8%	118,340 $175,000

Q4 2022 Feb 14, 2023	SELL	$1.2 - $2.49 $14,462 - $30,009	-12,052 Reduced 28.42%	30,359 $42,000
Q3 2022 Nov 14, 2022	SELL	$2.97 - $5.19 $8,749 - $15,289	-2,946 Reduced 6.5%	42,411 $117,000
Q2 2022 Oct 27, 2022	SELL	$3.38 - $5.27 $84,780 - $132,187	-25,083 Reduced 35.61%	45,357 $213,000
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.27 $84,780 - $132,187	-25,083 Reduced 35.61%	45,357 $213,000
Q1 2022 Oct 27, 2022	BUY	$4.76 - $6.24 $119,395 - $156,517	25,083 Added 55.3%	70,440 $342,000
Q1 2022 May 13, 2022	SELL	$4.76 - $6.24 $11,709 - $15,350	-2,460 Reduced 3.37%	70,440 $342,000
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $470,774 - $751,587	-82,592 Reduced 53.12%	72,900 $438,000
Q3 2021 Nov 15, 2021	BUY	$6.74 - $8.02 $1.05 Million - $1.25 Million	155,492 New	155,492 $1.05 Million

Others Institutions Holding NXTC

# of Institutions

Shares Held

16.1M

Call Options Held

10.5K

Put Options Held

View Full List

About NextCure, Inc.

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $42.7M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

More about NXTC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account